March 17th 2023
In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.
FDA Approves Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
March 23rd 2022The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.
Read More
Better Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC Compared to Sunitinib
February 19th 2022A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.
Read More
Upfront Avelumab Maintenance Demonstrates Continued OS Benefit in Advanced UC
February 18th 2022An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Read More
PFS Prolonged With Continuous Enzalutamide After AR Inhibitor Progression in mCRPC
February 18th 2022According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Read More
TAK-700 Achieves Limited Overall Survival Improvement in mHSPC
June 8th 2021Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.
Read More
Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint Inhibitors
May 17th 2021Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines
Read More